Supply agreement enables development of POINT’s next-generation Ac-225-based radioligand therapies. INDIANAPOLIS and TORONTO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT ...

BELOIT, Wis. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for ...

NorthStar to provide non-carrier added actinium-225 (n.c.a Ac-225) to Cellectar for use in its expanded portfolio of clinical programs This includes CLR 121225 an actinium-labeled phospholipid ether ...

NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into ...

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs. The U.S. Food and Drug Administration recently acknowledged ...

Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...

HAMILTON, ON, Dec. 18, 2025 /CNW/ - AtomVie Global Radiopharma (AtomVie), a global radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in GMP manufacturing and ...

In experiment after experiment, the synthetic radioisotope actinium-225 has shown promise for targeting and attacking certain types of cancer cells. Although researchers have studied this radioisotope ...

TerraPower Isotopes and Belgian joint venture PanTera have announced a collaboration to increase the global availability of actinium-225, while Arizona-based Serva Energy has developed a new research ...

BELOIT, Wis. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC (‘NorthStar’), a global innovator in the development, production and commercialization of radiopharmaceuticals ...